Metadherin emerges as an invasion switch in oral squamous cell carcinoma

Oral squamous cell carcinoma, the most common malignancy of the oral cavity, remains one of the most stubborn cancers to treat despite decades of progress in surgery, radiation, and chemotherapy. For patients with aggressive tumors, the options are limited and the outcomes are often grim, which is precisely why a new study from researchers at Seoul National University and international collaborators has drawn attention across the head and neck oncology community. The work, published in Cancer Cell International, points to a single stress-responsive protein called metadherin, or MTDH, as a central driver of the invasive behavior that makes these tumors so dangerous. What makes the finding especially striking is the selectivity of the mechanism: MTDH appears to reprogram how cancer cells move and invade without broadly disrupting the cell’s entire genetic machinery, a property that could make it an unusually clean target for precision therapy.

Metadherin is not a new name in cancer biology. The gene, also known as AEG-1, was originally identified because it is switched on when cells are under stress, and it has since been found at elevated levels in a wide range of malignancies, from breast and liver cancer to glioblastoma. Researchers have proposed that it functions as a so-called cancer fitness gene, helping tumors survive hostile conditions such as hypoxia and nutrient deprivation while simultaneously promoting metastasis. Yet in oral squamous cell carcinoma specifically, the protein’s role had never been fully characterized. The research team, led by Sak Lee and Dong-Guk Park of Seoul National University’s Department of Oral Pathology, together with senior authors Seong-Doo Hong and Sung-Dae Cho, set out to close that gap with a combination of patient tissue analysis, genetic engineering, and genome-wide transcriptomics.

The first step was spatial. The investigators examined immunohistochemical staining from 100 surgically resected oral squamous cell carcinoma specimens, looking not just at whether MTDH was present but where within each tumor it accumulated. The answer was revealing. Rather than being uniformly distributed, MTDH expression was enriched at the invasive front of the tumors, the leading edge where cancer cells detach from the main mass and burrow into surrounding tissue, compared with the tumor center. This spatial heterogeneity matters because the invasive front is where the clinically decisive behavior of a tumor happens. It is the zone that pathologists scrutinize when grading aggressiveness, and it is the region whose cells ultimately determine whether the cancer spreads to lymph nodes and beyond.

That spatial pattern translated directly into clinical behavior. High MTDH expression was significantly associated with non-cohesive invasion patterns, meaning tumors in which cancer cells infiltrate surrounding tissue as single cells or loose strands rather than as coherent, pushing borders. In the standardized classification used by oral pathologists, known as the worst pattern of invasion, non-cohesive growth is among the most ominous findings, correlating with increased risk of nodal metastasis and poorer survival. The implication is that MTDH is not merely a passive marker that happens to be present in aggressive tumors; its location and abundance track with the very morphological features that clinicians use to predict how a cancer will behave.

To test whether MTDH actually causes invasive behavior rather than simply accompanying it, the team turned to CRISPR/Cas9 gene editing. In oral squamous cell carcinoma cell lines, they knocked out the MTDH gene entirely and observed what happened. The results were unexpectedly clean. Cells lacking MTDH showed markedly suppressed migration and invasion in laboratory assays, confirming the protein’s functional role in motility. Yet their proliferation was unaffected, and apoptosis, the programmed cell death pathway that many cancer therapies rely on triggering, was untouched. In other words, removing MTDH uncoupled the invasive capacity of the cancer cells from their ability to grow and divide. This dissociation is scientifically fascinating and therapeutically significant, because it suggests that an MTDH-targeted drug could, in principle, blunt a tumor’s ability to spread without necessarily needing to kill the cells outright.

The next question was how MTDH exerts this effect at the molecular level. When the researchers performed transcriptomic profiling, sequencing the RNA of knockout cells versus controls, they expected, perhaps, to find wholesale changes in gene expression. Instead, they found the opposite. MTDH loss produced selective transcriptional modulation rather than global upheaval. Only a restricted set of genes responded to the knockout, a finding that runs counter to the intuition that a protein involved in such a fundamental behavior as invasion would pull on many levers at once. Within that small repertoire, one gene stood out for its consistency: keratin 14, or KRT14, a structural protein of the epithelial cytoskeleton that was reliably downregulated when MTDH was removed.

The connection between MTDH and KRT14 held up across multiple levels of analysis. The two genes’ expression correlated positively at both the transcript level, measured by quantitative reverse transcription polymerase chain reaction and RNA sequencing, and the protein level, measured in patient tissue. Keratin 14 is a well-known marker of basal-like epithelial cells and has been implicated in the epithelial-mesenchymal transition, the developmental program that cancer cells hijack to become mobile and invasive. A cytoskeletal keratin might seem an odd accomplice for metastasis, but the architecture of the cell is precisely what must be remodeled for a firmly anchored epithelial cell to crawl through tissue. By selectively tuning KRT14, MTDH may be adjusting the mechanical and structural state of the cancer cell to favor movement over cohesion.

The selectivity of this mechanism carries real implications for drug development. Many candidate cancer targets fail in translation because they are so deeply embedded in normal cellular physiology that inhibiting them causes unacceptable toxicity. A target whose perturbation produces a narrow, focused transcriptional response, confined largely to invasion-related programs rather than a cascade of downstream chaos, is inherently more attractive. The authors argue that their findings support MTDH as a precision therapeutic target for inhibiting invasion in oral squamous cell carcinoma, a disease in which local invasion into jawbone, muscle, and nerves often dictates the extent of disfiguring surgery and the likelihood of recurrence even when distant metastasis has not yet occurred.

There are, of course, caveats that temper the enthusiasm. The study relied on cell line models and retrospective analysis of patient specimens, and the leap from laboratory knockout to a clinically deployable inhibitor remains long. Whether pharmacological blockade of MTDH in patients would reproduce the clean phenotype seen in CRISPR-edited cells is an open question, as is the behavior of tumors in which MTDH-independent pathways compensate for its loss. The work was supported by the National Research Foundation of Korea and is based in part on the doctoral dissertation of the first author, reflecting the incremental, carefully validated nature of the evidence. Still, the convergence of spatial pathology, functional genetics, and transcriptomics on a single coherent story gives the finding unusual weight.

For the field of head and neck oncology, the study adds a potentially decisive piece to the puzzle of why some oral cancers spread aggressively while others remain indolent. It reframes metadherin from a broad stress-response player into a specific, spatially localized regulator of the invasive front, acting through keratin 14 to restructure the cytoskeletal machinery of migration. If subsequent studies confirm the pathway and yield tractable ways to inhibit it, clinicians may one day add an anti-invasion agent to the multimodal arsenal, one that disarms the deadliest behavior of oral squamous cell carcinoma while leaving the rest of the cell, and hopefully the patient, largely undisturbed. In a cancer where the difference between cure and catastrophe often comes down to a few millimeters of invasion at the tumor’s edge, that would be no small achievement.

Subject of Research: The role of metadherin in regulating invasion and keratin 14 expression in oral squamous cell carcinoma

Article Title: Metadherin at the invasive front drives OSCC via selective KRT14 regulation

Article References: Lee, S., Park, D.-G., Kim, H.-J., Lee, J.-H., Choi, S.-J., Kuk, S. K., Yoon, H.-J., Kwon, I.-J., Porntaveetus, T., Hong, S.-D., & Cho, S.-D. (2026). Metadherin at the invasive front drives OSCC via selective KRT14 regulation. Cancer Cell International. https://doi.org/10.1186/s12935-026-04481-2

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04481-2

Keywords: metadherin, MTDH, oral squamous cell carcinoma, keratin 14, KRT14, cancer invasion, CRISPR, metastasis, transcriptomics, invasive front, head and neck cancer, precision therapy